United Therapeutics CEO sells 1,500 shares

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt sold 1,500 shares of common stock in an open‑market transaction.

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt sold 1,500 shares of common stock in an open‑market transaction. The sale occurred on May 26, 2026 at a weighted average price of $575.9649 per share, leaving her with 43,153 shares directly held afterward.

The shares sold were acquired through an option exercise and the transaction was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. This Form 4/A amendment corrects the transaction code from a purchase to the proper sale code while keeping the disposition and share counts consistent.

Insider Trade Summary 10b5-1

Net Seller: 1,500 shares

Net Sell 1 txn

Insider ROTHBLATT MARTINE A

Role Chairperson & CEO

Sold 1,500 shs ($864K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,500	$575.9649	$864K

Holdings After Transaction: Common Stock — 43,153 shares (Direct)

Footnotes (3)

1. F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.
2. F2. The Form 4 being amended originally used transaction code P as a result of administrative error. This amendment is being filed to use the correct transaction code S. The transaction was at all times reported as a disposition of shares: the original Form 4 designated the shares as Disposed of "(D)" in Column 4, reported a corresponding reduction in the Amount of Securities Beneficially Owned Following the Reported Transaction (from 44,653 shares to 43,153 shares), and, as described in footnote 1, disclosed that the transaction was a sale of shares acquired on option exercise pursuant to the reporting person's Rule 10b5-1 trading plan.
3. F3. This transaction was executed in multiple trades at prices ranging from $575.51 to $576.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 1,500 shares Weighted average sale price: $575.9649 per share Post-transaction holdings: 43,153 shares +3 more

6 metrics

Shares sold 1,500 shares Open-market sale on May 26, 2026

Weighted average sale price $575.9649 per share Common stock sale on May 26, 2026

Post-transaction holdings 43,153 shares Common stock directly held after sale

Options under 10b5-1 plan 1,734,410 stock options Plan continues until exercise of these or December 31, 2026

Option expiration date March 17, 2027 Expiration for stock options covered by plan

Plan end date December 31, 2026 Latest date for Rule 10b5-1 plan effectiveness

Key Terms

Rule 10b5-1 trading plan, weighted average price, stock options, Form 4, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above reflects the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

stock options financial

"the exercise of 1,734,410 stock options, all of which expire on March 17, 2027"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Form 4 regulatory

"The Form 4 being amended originally used transaction code P as a result of administrative error."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code S regulatory

"This amendment is being filed to use the correct transaction code S."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did UNITED THERAPEUTICS (UTHR) report for its CEO?

UNITED THERAPEUTICS reported that CEO Martine A. Rothblatt sold 1,500 shares of common stock. The open‑market sale occurred on May 26, 2026 and involved shares acquired via option exercise under her pre‑arranged Rule 10b5‑1 trading plan.

At what price did the UNITED THERAPEUTICS (UTHR) CEO sell shares on May 26, 2026?

The CEO’s 1,500 shares were sold at a weighted average price of $575.9649 per share. Footnotes note multiple trades executed between $575.51 and $576.50, with the reported figure representing the overall weighted average for the transaction.

How many UNITED THERAPEUTICS (UTHR) shares does the CEO hold after this Form 4/A transaction?

After selling 1,500 shares, CEO Martine A. Rothblatt directly holds 43,153 shares of UNITED THERAPEUTICS common stock. The filing shows this reduced balance in the “Amount of Securities Beneficially Owned Following the Reported Transaction” column for the non‑derivative holdings.

Was the UNITED THERAPEUTICS (UTHR) CEO’s share sale under a Rule 10b5-1 trading plan?

Yes. The filing states the option exercise and resulting share sale were under a pre‑arranged Rule 10b5‑1 plan. The plan was adopted on November 7, 2025 and governs exercises of stock options and related sales during the specified period.

What does this Form 4/A amendment change for UNITED THERAPEUTICS (UTHR)?

The amendment corrects the transaction code from P (purchase) to S (sale). The filing explains the original Form 4 used code P by administrative error, while the transaction was always reported as a disposition with a reduced post‑transaction share balance.

What stock options are covered by the UNITED THERAPEUTICS (UTHR) CEO’s 10b5-1 plan?

The Rule 10b5‑1 plan covers the exercise of up to 1,734,410 stock options. According to the footnote, all these options expire on March 17, 2027, and the plan ends when they are exercised or on December 31, 2026, whichever occurs first.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairperson & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/27/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		S(1)(2)		1,500	D	$575.9649(3)	43,153	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

2. The Form 4 being amended originally used transaction code P as a result of administrative error. This amendment is being filed to use the correct transaction code S. The transaction was at all times reported as a disposition of shares: the original Form 4 designated the shares as Disposed of "(D)" in Column 4, reported a corresponding reduction in the Amount of Securities Beneficially Owned Following the Reported Transaction (from 44,653 shares to 43,153 shares), and, as described in footnote 1, disclosed that the transaction was a sale of shares acquired on option exercise pursuant to the reporting person's Rule 10b5-1 trading plan.

3. This transaction was executed in multiple trades at prices ranging from $575.51 to $576.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)